The detail
STEP trials used 2.4 mg semaglutide. Doses below 1 mg show diminishing weight loss returns. Microdosing claims often unverified anecdotal. May offer reduced side effects during slight metabolic benefits, but shouldn't expect major weight loss. Not FDA-approved approach.
Historical context
"Microdosing" GLP-1 is a popular term, not a defined medical regimen. It emerged largely from social media and cost-driven access patterns during shortages, rather than from a studied dosing strategy.
Research landscape
The approved GLP-1 medications were studied at specific therapeutic doses, and their weight and metabolic benefits are tied to those doses. Deliberately using very low ("micro") doses sits outside that evidence base: in general, sub-therapeutic dosing produces proportionally smaller effects, and there is little rigorous data on low-dose maintenance after weight loss. Some clinicians explore lower maintenance doses for individuals who reached a goal and tolerate less, but this is individualized and not a validated protocol. Claims that microdosing delivers full benefits at a fraction of the dose are not supported by the trial evidence.
What providers actually do
An honest prescriber distinguishes "starting low and titrating" (standard practice to limit side effects) from "staying permanently at a sub-therapeutic micro-dose" (unstudied). They also flag that compounded products marketed for microdosing carry the usual non-FDA-approved sourcing and potency caveats.
Subtle red flags specific to this question
- A provider promising full results from a fraction of the studied dose — the evidence does not support that.
- Sourcing "microdose" vials from a pharmacy that will not verify potency or provide a certificate of analysis.
- Using microdosing to stretch a supply while skipping medical follow-up — monitoring still matters.
- Assuming a lower dose means no side effects — nausea and GI effects can still occur.
Sources
Was this helpful?